ELANE and breast carcinoma: Analysis of a second microarray dataset [25] supported these findings and showed that patients with the combination of high levels of elastase (ELA2) expression concomitant with low levels of elafin expression were more likely to relapse and die from their breast cancer sooner after diagnosis than patients with high elafin expression and low elastase expression (P = .05, Figure 6E).